Glenmark Pharmaceuticals Ltd.

NSE: GLENMARK · Healthcare

₹2,590.00+4.36%06 Nov 2026

Check figures: unusual quarterly results in JUN '26 (₹482.92 cr vs a typical ₹2.38 cr). This may be a filing error (e.g. lakh filed as crore) or a genuine one-off; figures are shown as filed. Trailing-twelve-month figures include it.

Ask the data

Instant answers about Glenmark Pharmaceuticals Ltd. — computed from its filings, no language model

Market cap₹73,095 cr

Current price₹2,590.00

High / Low₹2,590 / ₹1,810

P/E82.5

P/B6.52

Book value₹397.3

ROE7.9%

ROCE17.4%

Debt / equity0.08

Dividend yield0.19%

EPS (TTM)₹31.40

Face value₹1

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

showing latest 6 of 9 periods

	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Revenue	9,103	9,865	10,641	10,944	12,305	12,990	11,813	13,322	16,983
EBITDA	1,615	1,586	1,698	2,084	2,320	2,278	1,195	2,351	4,572
Operating margin	17.7%	16.1%	16.0%	19.0%	18.9%	17.5%	10.1%	17.7%	26.9%
Interest	286	335	377	353	298	350	516	207	209
Depreciation	302	326	417	444	487	611	582	486	573
Profit before tax	1,119	1,301	1,096	1,382	1,441	868	36	1,399	1,985
Tax	315	376	320	412	448	491	1,867	352	623
Net profit	0	0	0	0	942	0	-1,502	1,047	0
EPS ₹	28.49	32.78	27.50	34.38	33.37	10.53	-53.22	37.11	48.26
Operating cash flow	—	—	—	—	1,109	625	-265	-828	3,445
Capex	—	—	—	—	790	608	898	750	1,358
Dividend paid	—	—	—	—	93	137	118	70	141
Total assets	12,595	13,296	14,685	15,604	17,083	19,372	14,359	16,050	19,908
Equity	5,163	5,605	6,070	7,065	9,087	9,474	7,848	8,849	10,512

Quarterly performance

last 34 quarters · ₹ crore

showing latest 8 of 34 periods

	MAR '18	SEP '18	DEC '18	MAR '19	JUN '19	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
Revenue	2,280	2,581	2,555	2,563	2,323	2,815	2,736	2,767	2,345	2,952	2,787	2,860	2,965	3,147	3,173	3,019	2,777	3,375	3,464	3,374	3,402	3,207	2,507	3,063	3,244	3,434	3,388	3,256	3,264	6,047	3,901	3,771	4,018	4,157
Operating profit	327	440	435	364	342	450	440	466	478	553	530	523	574	590	693	463	432	622	620	605	631	462	-209	504	588	602	600	561	581	2,360	870	763	805	774
Operating margin	14.3%	17.0%	17.0%	14.2%	14.7%	16.0%	16.1%	16.8%	20.4%	18.7%	19.0%	18.3%	19.3%	18.8%	21.8%	15.3%	15.5%	18.4%	17.9%	17.9%	18.6%	14.4%	-8.3%	16.5%	18.1%	17.5%	17.7%	17.2%	17.8%	39.0%	22.3%	20.2%	20.0%	18.6%
Other income	70	140	-109	39	2	81	33	44	59	-32	15	8	59	-13	14	107	183	97	76	-40	21	2	45	773	31	39	31	12	26	201	44	189	66	93
Interest	74	85	89	82	93	90	96	98	94	81	95	83	76	69	67	87	60	83	97	109	112	121	134	149	40	48	52	67	58	66	41	43	54	64
Depreciation	74	82	83	81	91	94	106	126	113	104	115	111	113	123	119	132	147	156	162	147	155	141	147	151	118	120	123	125	130	141	154	148	173	180
Profit before tax	248	580	154	240	160	347	271	318	358	339	348	338	444	385	343	270	408	480	471	-491	333	-124	-521	531	462	473	456	8	96	967	534	388	643	338
Tax	97	166	38	79	51	92	80	98	104	105	100	104	137	110	103	97	197	202	180	-88	160	56	-72	1,769	122	118	108	4	49	357	131	86	161	74
Net profit	0	368	166	0	0	0	191	0	0	0	0	0	399	0	0	156	193	0	291	0	23	-82	-351	-1,218	340	0	0	5	47	610	403	-0	483	0
EPS ₹	5.37	14.67	4.12	5.73	3.87	9.06	13.52	7.81	9.00	8.29	8.80	8.29	10.86	9.74	7.86	5.51	6.82	9.23	9.66	-15.18	5.31	-2.90	-12.45	-43.18	12.06	12.55	12.33	0.16	1.66	21.63	14.29	10.68	17.11	9.35
Revenue YoY	—	—	—	12.4%	—	9.1%	7.1%	8.0%	0.9%	4.9%	1.9%	3.3%	26.4%	6.6%	13.9%	5.6%	-6.3%	7.2%	9.2%	11.7%	22.5%	-5.0%	-27.6%	-9.2%	-4.6%	7.1%	35.1%	6.3%	0.6%	76.1%	15.1%	15.8%	23.1%	-31.3%
Profit YoY	—	—	—	—	—	-100.0%	14.8%	—	—	—	-100.0%	—	—	—	—	—	-51.8%	—	—	-100.0%	-88.0%	—	-220.8%	—	1367.2%	—	—	—	-86.2%	—	—	-102.2%	930.3%	-100.0%

Earlier results (standalone, Sep '07 – Dec '17)

₹ crore · from BSE, before the NSE XBRL filings begin

Glenmark Pharmaceuticals Ltd. reports consolidated figures above. Quarterly consolidated results only became mandatory in India in 2019, so the earlier history available is the standalone company only (excluding subsidiaries). It is shown separately so the two bases are never mixed.

Full years

	FY09†	FY10†	FY12†	FY13†	FY14†	FY15†	FY16†	FY17†
Revenue	856	1,023	1,565	1,949	2,301	5,086	6,114	8,069
Operating profit	222	164	311	332	496	1,465	1,756	2,899
Operating margin	25.9%	16.0%	19.9%	17.1%	21.6%	28.8%	28.7%	35.9%
Other income	99	8	55	116	67	85	117	148
Interest	55	30	61	44	31	30	36	153
Depreciation	19	21	21	25	30	119	112	105
Profit before tax	246	121	284	380	502	1,232	1,725	2,553
Tax	28	-7	19	-6	68	224	256	410
Net profit	218	128	265	386	434	1,008	1,468	2,143

Quarters

showing latest 8 of 41 periods

	SEP '07†	DEC '07†	MAR '08†	JUN '08†	SEP '08†	DEC '08†	MAR '09†	JUN '09†	SEP '09†	DEC '09†	MAR '10†	JUN '10†	SEP '10†	DEC '10†	JUN '11†	SEP '11†	DEC '11†	MAR '12†	JUN '12†	SEP '12†	DEC '12†	MAR '13†	JUN '13†	SEP '13†	DEC '13†	MAR '14†	JUN '14†	SEP '14†	DEC '14†	MAR '15†	JUN '15†	SEP '15†	DEC '15†	MAR '16†	JUN '16†	SEP '16†	DEC '16†	MAR '17†	JUN '17†	SEP '17†	DEC '17†
Revenue	279	434	397	194	226	245	191	220	236	277	289	257	293	319	327	383	399	456	392	529	543	485	509	585	532	674	616	693	657	3,119	1,248	1,566	1,394	1,906	1,641	2,171	2,192	2,065	1,548	1,660	1,557
Operating profit	97	195	115	47	76	80	19	6	63	55	40	55	64	74	106	40	20	145	66	99	110	58	131	112	76	176	122	127	131	1,085	428	467	348	513	601	781	844	672	353	397	267
Operating margin	34.7%	45.0%	29.1%	24.3%	33.7%	32.5%	9.9%	2.9%	26.6%	19.9%	13.8%	21.4%	21.9%	23.1%	32.3%	10.4%	5.0%	31.9%	16.7%	18.7%	20.2%	12.0%	25.8%	19.2%	14.3%	26.1%	19.8%	18.3%	20.0%	34.8%	34.3%	29.8%	24.9%	26.9%	36.6%	36.0%	38.5%	32.5%	22.8%	23.9%	17.1%
Other income	2	2	15	0	25	9	64	2	3	0	4	31	-23	11	4	1	4	47	12	64	13	27	22	21	11	13	15	19	12	39	26	27	-3	67	98	-6	106	-50	43	56	37
Interest	11	12	9	9	16	24	5	2	7	11	9	8	10	8	13	0	2	45	11	15	11	6	9	6	8	7	7	9	7	7	8	9	8	10	11	42	50	50	46	47	47
Depreciation	8	8	8	4	5	5	5	5	5	5	5	5	5	5	5	5	5	6	6	6	6	6	7	7	8	8	9	8	8	95	27	28	28	29	25	26	26	27	30	29	30
Profit before tax	80	178	113	34	81	60	72	1	53	39	29	73	26	72	91	36	16	141	61	141	105	72	138	120	71	173	122	129	128	853	419	457	308	540	662	707	875	308	320	377	227
Tax	16	31	-17	-23	14	23	15	-4	-5	1	0	12	-2	14	19	4	3	-7	6	4	-4	-13	20	14	13	22	18	13	11	182	84	90	50	33	144	152	164	-49	49	50	33
Net profit	64	146	130	57	67	37	57	5	58	37	28	61	28	58	72	31	13	148	55	137	109	85	118	106	58	152	104	116	117	670	335	367	259	508	519	556	711	357	271	328	194
EPS ₹	2.62	5.97	5.24	2.28	2.67	1.47	2.29	0.21	2.27	1.39	1.05	2.25	1.02	2.15	2.68	1.16	0.49	5.48	2.03	5.07	4.03	3.14	4.35	3.91	2.15	5.59	3.83	4.29	4.30	24.71	12.13	13.00	9.17	18.00	18.39	19.70	25.21	12.65	9.60	11.62	6.88
Revenue YoY	—	—	—	—	-19.1%	-43.6%	-51.8%	13.5%	4.5%	13.3%	51.2%	16.9%	24.3%	15.0%	27.2%	30.5%	25.3%	—	20.0%	38.2%	35.9%	6.5%	29.8%	10.6%	-2.0%	38.9%	21.0%	18.4%	23.6%	362.6%	102.4%	125.9%	112.1%	-38.9%	31.5%	38.7%	57.2%	8.4%	-5.7%	-23.6%	-29.0%
Profit YoY	—	—	—	—	4.7%	-74.8%	-56.0%	-90.8%	-14.0%	1.5%	-50.7%	1064.6%	-52.1%	54.6%	19.2%	14.2%	-77.3%	—	-24.3%	336.5%	729.8%	-42.7%	114.8%	-22.9%	-46.4%	78.6%	-11.8%	9.9%	99.8%	342.0%	222.5%	215.0%	121.7%	-24.3%	54.8%	51.6%	174.9%	-29.7%	-47.8%	-41.0%	-72.7%

Returns & margins

trailing-twelve-month, per quarter

showing latest 8 of 30 periods

	JUN '19	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
ROE	9.5%	3.0%	3.4%	3.1%	3.1%	3.1%	0.0%	0.0%	5.6%	5.6%	5.6%	6.1%	3.8%	3.6%	6.7%	5.1%	3.3%	2.5%	-4.4%	-20.7%	-16.7%	-14.6%	-10.4%	3.9%	0.6%	6.9%	11.1%	10.1%	14.2%	7.9%
ROCE	15.6%	13.2%	14.5%	24.3%	27.5%	27.3%	28.5%	14.8%	15.3%	15.6%	15.3%	13.6%	13.2%	13.3%	14.5%	8.8%	8.6%	4.4%	-2.3%	8.3%	9.0%	13.1%	22.1%	14.5%	11.4%	16.9%	17.5%	20.9%	26.0%	17.4%
Net margin	5.3%	1.6%	1.8%	1.8%	1.8%	1.8%	0.0%	0.0%	3.5%	3.4%	3.3%	4.5%	2.9%	2.8%	5.1%	3.7%	2.3%	1.7%	-3.3%	-13.4%	-10.9%	-10.0%	-6.7%	2.6%	0.4%	4.1%	6.5%	6.2%	8.4%	5.6%
EBITDA margin	15.8%	15.5%	15.3%	16.0%	17.2%	17.9%	18.7%	19.0%	18.9%	18.9%	19.6%	18.9%	18.0%	17.9%	16.9%	17.5%	18.2%	17.2%	11.9%	11.4%	11.2%	12.1%	17.5%	17.7%	17.6%	25.7%	26.5%	26.9%	27.0%	20.3%
Debt / equity	0.69	0.69	0.69	—	—	—	—	0.66	0.66	0.66	0.66	0.40	0.40	0.41	0.41	0.46	0.46	0.53	0.53	0.13	0.13	0.18	0.18	0.25	0.25	0.09	0.09	0.00	0.00	0.08
Interest coverage	4.25	3.55	3.82	3.90	4.42	4.49	4.70	4.92	5.38	5.68	6.12	5.83	5.98	6.06	5.98	3.48	2.98	1.43	-0.68	1.42	1.78	3.55	7.65	7.76	5.57	7.27	7.89	10.51	13.38	10.43
Asset turnover	0.75	0.77	0.78	0.72	0.73	0.74	0.74	0.70	0.74	0.75	0.78	0.72	0.71	0.68	0.70	0.67	0.70	0.67	0.62	0.85	0.84	0.80	0.86	0.83	0.83	0.84	0.87	0.85	0.89	0.74

Balance sheet

equity vs borrowings over time · ₹ crore

showing latest 6 of 16 periods

	MAR '16‡	MAR '17‡	MAR '18‡	MAR '19‡	MAR '20‡	MAR '21‡	MAR '22‡	SEP '22	MAR '23	SEP '23	MAR '24	SEP '24	MAR '25	SEP '25	MAR '26	SEP '26
Share capital	28	28	28	28	—	28	28	28	28	28	28	28	28	28	28	28
Other equity / reserves	3,601	4,464	5,135	5,577	—	7,036	9,058	9,545	9,446	9,299	7,820	8,417	8,821	9,554	10,484	11,184
Total equity	3,630	4,493	5,163	5,605	6,070	7,065	9,087	9,573	9,474	9,327	7,848	8,446	8,849	9,582	10,512	11,212
Borrowings	3,275	4,724	4,437	3,877	—	4,687	3,670	3,954	4,348	4,921	991	1,562	2,194	892	0	867
Current liabilities	3,999	2,703	3,288	4,021	4,126	4,201	4,689	4,198	5,046	5,290	5,819	6,185	5,967	6,960	6,376	7,507
Non-current liabilities	2,564	4,569	4,144	3,670	4,489	4,338	2,956	3,894	4,487	4,433	692	605	1,233	2,461	3,020	2,681
Total assets	10,193	11,764	12,595	13,296	14,685	15,604	17,083	18,031	19,372	20,006	14,359	15,235	16,050	19,002	19,908	21,400
Property, plant & equipment	1,644	1,784	1,896	2,098	—	2,693	3,442	3,728	3,904	3,104	3,118	3,155	3,319	3,399	3,890	3,307
Capital work-in-progress	498	630	993	1,234	—	1,218	921	1,176	1,115	1,221	419	395	542	695	428	599
Investments	17	16	15	30	—	25	50	45	45	45	790	45	56	42	42	42
Inventories	1,568	2,139	2,031	2,252	—	2,277	2,500	2,865	2,978	2,650	2,513	2,840	3,029	3,281	3,431	3,746
Receivables	—	2,404	2,332	2,195	—	2,572	3,101	3,328	4,099	3,200	1,858	2,863	3,342	3,773	4,963	5,494
Cash & equivalents	857	1,056	1,233	936	—	1,138	1,411	1,239	1,443	1,123	1,658	1,819	1,676	2,647	1,175	1,290

Cash flow

annual · ₹ crore · line = free cash flow

showing latest 5 of 8 periods

	FY18‡	FY20‡	FY21‡	FY22	FY23	FY24	FY25	FY26
Cash from operations	1,648	1,392	1,131	1,109	625	-265	-828	3,445
Cash from investing	-1,013	-784	-675	-333	-528	4,369	2	-1,283
Cash from financing	-468	-445	-442	-520	-77	-3,906	787	-2,709
Capex	1,045	—	775	790	608	898	750	1,358
Free cash flow	603	—	356	319	18	-1,164	-1,577	2,087
Dividends paid	—	—	—	93	137	118	70	141

Where the assets sit

Sep '26 · ₹ crore

Fixed assets (PPE)

₹3,307 cr15%

CWIP

₹599 cr3%

Investments

₹42 cr0%

Inventories

₹3,746 cr18%

Receivables

₹5,494 cr26%

Cash & equivalents

₹1,290 cr6%

Other assets

₹6,922 cr32%

Peer comparison

largest in Healthcare · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Sun Pharmaceutical Industries Ltd.	4,46,270	1,860.00	40.7	5.00	12.3%
Divi's Laboratories Ltd.	2,73,493	10,320.50	93.5	16.32	17.5%
Torrent Pharmaceuticals Ltd.	1,80,671	4,750.00	85.1	9.83	11.6%
Laurus Labs Ltd.	1,26,430	2,340.00	94.4	20.86	22.1%
Apollo Hospitals Enterprise Ltd.	1,21,453	8,446.00	54.2	11.45	21.1%
Zydus Lifesciences Ltd.	1,19,550	1,197.90	28.6	4.30	15.0%
Dr. Reddy's Laboratories Ltd.	1,14,646	1,373.00	40.9	2.95	7.2%
Cipla Ltd.	1,13,988	1,411.00	39.3	3.22	8.2%
Mankind Pharma Ltd.	1,04,902	2,540.00	46.7	5.97	12.8%
Aurobindo Pharma Ltd.	1,03,572	1,800.00	26.0	2.63	10.1%
Glenmark Pharmaceuticals Ltd.	73,095	2,590.00	82.5	6.52	7.9%

StoxGud checklist: Neutral setup · 5/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month+13.5%

6 months+9.2%

1 year+40.5%

3Y CAGR+50.8%

5Y CAGR+37.6%

10Y CAGR+11.2%

50-day avg₹2,368.01

200-day avg₹2,234.78

RSI (14)79

Long-term financials (FY16–FY16)

from published annual reports

Year	Revenue	Profit before tax	Net profit
FY16	₹7,662 Cr	—	₹702 Cr

Years before FY17 follow the older Indian GAAP standard, so they are not exactly comparable with recent years.

Compare Glenmark Pharmaceuticals Ltd. with

Lupin vs Glenmark Pharmaceuticals Max Healthcare Institute vs Glenmark Pharmaceuticals Glenmark Pharmaceuticals vs Alkem Laboratories Glenmark Pharmaceuticals vs Biocon

FAQs

What is the share price of Glenmark Pharmaceuticals Ltd.?

Glenmark Pharmaceuticals Ltd. (GLENMARK) closed at ₹2,590.00 on NSE on 06 Nov 2026.

What is the market cap of Glenmark Pharmaceuticals Ltd.?

₹73,095 crore at the latest close.

What is the P/E ratio of Glenmark Pharmaceuticals Ltd.?

82.5, on trailing-twelve-month earnings from its filings.

How fast is Glenmark Pharmaceuticals Ltd. growing?

Glenmark Pharmaceuticals Ltd.: revenue has compounded at 9.3% a year over three years. Latest-quarter revenue is down 31.3% year on year, profit down 100.0%.

How profitable is Glenmark Pharmaceuticals Ltd.?

On a trailing-twelve-month basis return on equity is 7.9%, return on capital employed 17.4%, operating margin 20.3%, net margin 5.6%.

How much debt does Glenmark Pharmaceuticals Ltd. have?

Glenmark Pharmaceuticals Ltd. is lightly geared: debt to equity is 0.08 with borrowings of ₹867 cr against cash of ₹1,290 cr (balance sheet of 2026-09-30). Operating profit covers interest 10.4 times.

Financials parsed from Glenmark Pharmaceuticals Ltd.'s own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from MAR '18, annual from FY18, balance sheet from Mar '16. * = derived (full year or half year minus earlier quarters). ‡ = balance sheet / cash flow read from the company's published annual report (same basis), for years before the NSE filings carry them; each one checked to add up. Information only, not investment advice.